FINWIRES · TerminalLIVE
FINWIRES

研究快訊:CFRA維持KKR & Co. Inc.股票的買進評等。

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:我們下調目標價5美元至125美元,採用更窄的股權風險溢價以反映對未來基金業績的擔憂,並將預期市盈率設定為19.8倍,接近五年歷史平均水平19.0倍,但低於三年平均水平21.8倍。公開市場的波動導致投資者對KKR股票的情緒因市場不確定性而轉為負面。 KKR的財務表現是多年前決策的結果,因此,其投資組合建構、風險規避和整體紀律應能使其基本面免受當前市場擔憂的影響。然而,我們認為私募股權投資的變現可能需要更長時間。我們預計2026年和2027年的調整後淨利潤分別下調0.55美元至6.30美元和7.50美元,預計營收分別為101億美元(此前為105億美元)和115億美元(此前為126億美元)。我們認為,大型全球投資人正將投資集中於少數另類投資公司(ALT公司),KKR就是其中之一。儘管負面新聞不斷,但我們認為KKR已做好充分準備,一旦市場回暖,便可加速其變現。

Related Articles

Australia

Top Cryptocurrencies Rise; Bitcoin Tops $81,000

Major digital assets rose Tuesday with Bitcoin (BTC-USD) topping $81,000.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose almost 1.3% in the past 24 hours. The Nasdaq 100 was up 1.4%, the S&P 500 rose 0.9%, and the Dow Jones Industrial Average added 0.9%.Bitcoin rose 2% to $81,657, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume decreased 34% to $37.2 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, added 0.8% to $2,375.XRP (XRP-USD) gained 1%, BNB (BNB-USD) rose 1.1%, and Solana (SOL-USD) added 2.4%. Dogecoin (DOGE-USD) climbed 2.9%, while Cardano (ADA-USD) was up 2.9%.The US 10-year Treasury yield stood at 4.413% at 3 p.m. ET Tuesday, down from 4.447% Monday, while the five-year yield fell to 4.069% from 4.093%.The total market value of the cryptocurrency industry rose 1.7% in the past 24 hours to $2.69 trillion, with trading volume gaining 1.8% to $164.38 billion.Price: $81530.92, Change: $+1706.70, Percent Change: +2.14%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD
Research

Research Alert: CFRA Upholds Buy Rating On Shares Of Fiserv, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $70 from $83, on a P/E of 7.8x our 2027 EPS view vs. the peer average of 6.7x. We decrease our 2026 EPS view to $8.14 from $8.28 and 2027's to $9.00 from $9.17. Despite operational challenges, FISV maintained its 2026 guidance and commitment to shareholder returns. The company affirmed its expectation for organic revenue growth of 1%-3% and adjusted EPS of $8.00-$8.30 for 2026. FISV repurchased $200M worth of shares in Q1, demonstrating continued confidence in its long-term prospects. This confidence is directly tied to the tangible progress made under the "One Fiserv" action plan. Management highlighted key operational improvements, such as a 27% Y/Y reduction in client inquiry resolution time and strong underlying growth in platforms like Finxact and CommerceHub, as leading indicators that support the full-year guidance. We think the positive underlying trends will become more visible in the financial results in 2H 2026 and beyond.

$FISV
Insider Trading

Pharvaris Insider Sold Shares Worth $427,419, According to a Recent SEC Filing

Peng Lu, Chief Medical Officer, on May 01, 2026, sold 14,166 shares in Pharvaris (PHVS) for $427,419. Following the Form 4 filing with the SEC, Lu has control over a total of 66,083 common shares of the company, with 66,083 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526206273/xslF345X05/ownership.xmlPrice: $29.94, Change: $-0.08, Percent Change: -0.27%

$PHVS